Heparin-induced thrombocytopenia (HIT) is an immune complication of heparin therapy
caused by antibodies to complexes of platelet factor 4 (PF4) and heparin. Pathogenic …

This article describes the pharmacology of approved parenteral anticoagulants. These
include the indirect anticoagulants, unfractionated heparin (UFH), low-molecular-weight …

Heparin-induced thrombocytopenia (HIT) is a life and limb-threatening complication of
heparin exposure. Here, we review the pathogenesis, incidence, diagnosis, and …

Heparin has been recognized as a valuable anticoagulant and antithrombotic for several
decades and is still widely used in clinical practice for a variety of indications. The …

Venous thromboembolism (VTE) is a serious and often fatal medical condition with an
increasing incidence. Despite the changing landscape of VTE treatment with the introduction …

The content of these European Society of Cardiology (ESC) Guidelines has been published
for personal and educational use only. No commercial use is authorized. No part of the ESC …

Background: Heparin‐induced thrombocytopenia (HIT) is a prothrombotic adverse drug
reaction caused by heparin. As thrombocytopenia is common in hospitalized patients …

Heparin-induced thrombocytopenia is a profoundly dangerous, potentially lethal,
immunologically mediated adverse drug reaction to unfractionated heparin or, less …

This chapter describes the pharmacology of approved parenteral anticoagulants, including
the indirect anticoagulants, unfractionated heparin (UFH), low-molecular-weight heparins …

Background and Objective There is a clinical need for new oral anticoagulants to prevent
and treat thromboembolic diseases. Given its integral role in the coagulation cascade, factor …